[1]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342-347.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
 Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):342-347.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
点击复制

18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第4期
页码:
342-347
栏目:
出版日期:
2015-07-25

文章信息/Info

Title:
Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma
作者:
胡娜 吴永港 肖立志 谭延林 王云华
中南大学湘雅二医院PET/CT中心, 湖南长沙, 410011
Author(s):
Hu Na Wu Yonggang Xiao Lizhi Tan Yanlin Wang Yunhua
Department of PET/CT Center, the Second Xiangya Hospital, Central South University, Changsha 410011, China
关键词:
淋巴瘤正电子发射断层显像术体层摄影术X线计算机代谢活性参数
Keywords:
LymphomaPositron-emission tomographyTomography X-ray computedMetabolic activity parameter
DOI:
10.3760/cma.j.issn.1673-4114.2015.04.015
摘要:
PET/CT中PET图像分析方法主要为视觉评估法与定量或半定量参数分析法,其中,定量或半定量分析参数主要包括SUV、肿瘤代谢体积和病灶糖酵解总量。PET/CT集功能显像与解剖显像于一体,成为淋巴瘤最重要的影像检查设备。笔者主要综述18F-FDG PET/CT常用代谢活性参数及其在淋巴瘤中的应用。
Abstract:
PET image analysis mainly includes the visual assessment and quantitative or semiquantitative approaches,and the quantitative or semiquantitative parameters include SUV,metabolic tumor volume and total lesion glycolysis.PET/CT provides both metabolic and morphologic information,and becomes the most important imaging armamentarium in lymphoma.This article reviews major metabolic activity parameters of 18F-FDG PET/CT and their application in lymphoma.

参考文献/References:

[1] Jaskowiak CJ, Bianco JA, Perlman SB, et al. Influence of Recon-struction iterations on 18F-FDG PET/CT standardized uptake values[J]. J Nucl Med, 2005, 46(3):424-428.
[2] Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy[J]. J Clin Oncol, 2002, 20(5):1398-1404.
[3] Halfpenny W, Hain SF, Biassoni L, et al. FDG-PET. A possible prognostic factor in head and neck cancer[J]. Br J Cancer, 2002, 86(4):512-516.
[4] Cistaro A, Quartuccio N, Mojtahedi A, et al. Prediction of 2 years-survival in patients with stage I and Ⅱ non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantification[J]. Radiol Oncol, 2013, 47(3):219-223.
[5] Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2007, 69(4):1282-1289.
[6] Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom[J]. Int J Radiat Oncol Biol Phys, 2012, 82(3):1164-1171.
[7] Boellaard R, O’doherty MJ, Weber WA, et al. FDG PET and PET/CT:EANM procedure guidelines for tumour PET imaging:ver-sion 1.0[J]. Eur J Nucl Med Mol Imaging, 2010, 37(1):181-200.
[8] Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma:methodological evalu-ation on phantom experiments and patients[J]. Eur J Nucl Med Mol Imaging, 2014, 41(6):1113-1122.
[9] Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngo-laryngeal squamous cell carcinoma:comparison at CT, Mr imag-ing, and FDG PET and validation with surgical specimen[J]. Radi-ology, 2004, 233(1):93-100.
[10] Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma:prediction of therapeutic response and prognostic implications[J]. Ann Surg On-col, 2010, 17(10):2787-2794.
[11] Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2012, 39(1):27-38.
[12] Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in os-teosarcoma[J]. J Nucl Med, 2009, 50(3):340-347.
[13] Chung HH, Kwon HW, Kang KW, et al. Prognostic value of preop-erative metabolic tumor volume and total lesion glycolysis in pa-tients with epithelial ovarian cancer[J]. Ann Surg Oncol, 2012, 19(6):1966-1972.
[14] Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer[J]. Int J Radiat Oncol Biol Phys, 2007, 69(2):328-333.
[15] Arslan N, Tuncel M, Kuzhan O, et al. Evaluation of outcome pre-diction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer[J]. Ann Nucl Med, 2011, 25(6):406-413.
[16] Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma[J]. Cancer, 2013, 119(6):1195-1202.
[17] Szczuraszek K, Mazur G, Jeleń M, et al. Prognostic significance of Ki-67 antigen expression in non-Hodgkin’s lymphomas[J]. Anti-cancer Res, 2008, 28(2A):1113-1118.
[18] Brown DC, Gatter KC. Ki67 protein:the immaculate deception?[J]. Histopathology, 2002, 40(1):2-11.
[19] Endl E, Gerdes J. The Ki-67 protein:fascinating forms and an un-known function[J]. Exp Cell Res, 2000, 257(2):231-237.
[20] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4):1710-1715.
[21] Weber G. Enzymology of cancer cells(first of two parts)[J]. N Engl J Med, 1977, 296(9):486-492.
[22] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect:the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930):1029-1033.
[23] 梁颖, 吴宁, 方艳, 等. 侵袭性淋巴瘤18F标记的氟代脱氧葡萄糖摄取程度与Ki-67表达的相关性[J]. 中华肿瘤杂志, 2013, 35(5):356-360.
[24] Wu X, Pertovaara H, Korkola P, et al. Glucose metabolism corre-lated with cellular proliferation in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2012, 53(3):400-405.
[25] Papajík T, Myslive?ek M, Sedová Z, et al. Standardised uptake val-ue of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin’s lymphoma[J]. Eur J Haematol, 2011, 86(1):32-37.
[26] Tang B, Malysz J, Douglas-Nikitin V, et al. Correlating metabolic activity with cellular proliferation in follicular lymphomas[J]. Mol Imaging Biol, 2009, 11(5):296-302.
[27] Watanabe R, Tomita N, Takeuchi K, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2010, 51(2):279-283.
[28] Sch?der H, Noy A, G?nen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between in-dolent and aggressive non-Hodgkin’s lymphoma[J]. J Clin Oncol, 2005, 23(21):4643-4651.
[29] Hutchings M, Loft A, Hansen M, et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake[J]. Hematol Oncol, 2006, 24(3):146-150.
[30] Wu X, Pertovaara H, Korkola P, et al. Early interim PET/CT pre-dicts post-treatment response in diffuse large B-cell lymphoma[J]. Acta Oncol, 2014, 53(8):1093-1099.
[31] Baba S, Abe K, Isoda T, et al. Impact of FDG-PET/CT in the man-agement of lymphoma[J]. Ann Nucl Med, 2011, 25(10):701-716.
[32] Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3):325-329.
[33] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1):122S-150.
[34] Karam M, Ata A, Irish K, et al. FDG positron emission tomography/computed tomography scan May identify mantle cell lymphoma pa-tients with unusually favorable outcome[J]. Nucl Med Commun, 2009, 30(10):770-778.
[35] Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria:central review in the PRIMA study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(3):408-415.
[36] Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tu-mour volume is an Independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imag-ing, 2014, 41(11):2017-2022.
[37] Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages Ⅱ and Ⅲ of diffuse large B cell lymphoma without extranodal site involvement[J]. Ann Hematol, 2012, 91(5):697-703.
[38] Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma[J]. Cancer Sci, 2013, 104(12):1656-1661.
[39] Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma[J]. Cancer Sci, 2012, 103(3):477-482.
[40] Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1321-1329.
[41] Song MK, Chung JS, Shin HJ, et al. Clinical value of metabolic tu-mor volume by PET/CT in extranodal natural killer/T cell lym-phoma[J]. Leuk Res, 2013, 37(1):58-63.
[42] Esfahani SA, Heidari P, Halpern EF, et al. Baseline total lesion glycolysis measured with 18F-FDG PET/CT as a predictor of progres-sion-free survival in diffuse large B-cell lymphoma:a pilot study[J]. Am J Nucl Med Mol Imaging, 2013, 3(3):272-281.
[43] Manohar K, Mittal BR, Bhattacharya A, et al. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglu-cose positron emission tomography/computed tomography in pa-tients with high-grade non-Hodgkin’s lymphoma[J]. Nucl Med Commun, 2012, 33(9):974-981.
[44] Adams HJ, De Klerk JM, Fijnheer RA, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prog-nostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma[J]. Eur J Haematol, 2015, 94(6):532-539.
[45] Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Haematol, 2014, 92(5):382-389.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
 He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
 Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
 Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
 Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[5]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
 Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[6]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
 Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
 Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
 Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
 Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
 Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
 You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[12]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
 Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[13]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
 YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[14]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[15]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
 SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[16]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
 LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
[17]郑玉民,颜珏.18F-氟脱氧葡萄糖PET在恶性淋巴瘤中的应用[J].国际放射医学核医学杂志,2008,32(6):347.
 ZHENG Yu-min,YAN Jue.The role of 18F-fluorodeoxyglucoxe PET in malignant lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):347.
[18]秦文琼,高硕.PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
 Qin Wenqiong,Gao Shuo.Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
[19]段钰,邓小虎,徐迟峰,等.面部原发性外周T细胞淋巴瘤-非特指型18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2017,41(6):455.[doi:10.3760/cma.j.issn.1673-4114.2017.06.014]
[20]王剑杰,王雪鹃,蒲朝煜.恶性淋巴瘤的多模态显像研究进展[J].国际放射医学核医学杂志,2018,(4):363.[doi:10.3760/cma.j.issn.1673-4114.2018.04.014]
 Wang Jianjie,Wang Xuejuan,Pu Chaoyu.The research progress of multimodal imaging in malignant lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):363.[doi:10.3760/cma.j.issn.1673-4114.2018.04.014]

备注/Memo

备注/Memo:
收稿日期:2015-02-12。
通讯作者:王云华,Email:13973186448@139.com
更新日期/Last Update: 1900-01-01